🏥 A major concern for patients in healthcare facilities |
|
|
Some bacteria in this family are resistant to almost all antibiotics, which reduces the available treatment options. This, combined with their rapid ability to spread and the risk of outbreaks, can also lead to a significant impact on healthcare costs. |
|
|
|
| of mortality rates reported in patients with severe CRE infections.1 |
|
| | of mortality rates observed in patients with CRE bloodstream.1 |
|
|
|
|
|
|
|
|
|
|
|
💰 The impact on the healthcare system |
|
|
| USA estimated annual healthcare costs associated with CRE infections.2 |
|
| | Costs for 16 patients carrying a carbapenemase-producing CRE over 2 years in France.3 |
|
| | Cost of a CRE outbreak in five hospitals in the UK over 10 months.4 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
The best selective and differential medium for detection of Carbapenem-Resistant Enterobacteriaceae |
|
|
 | CRE E. coli Dark pink to reddish |
|
|  | CRE Klebsiella, Enterobacter, Citrobacter Metallic blue |
|
|  | CRO* Pseudomonas Translucent cream to blue |
|
|  | CRO* Acinetobacter Cream, opaque |
|
|
|
|
|
|
|
|
|
|
|
|
🔬 Differentiation of most CRO* |
|
| Designed to detect a wide range of carbapenemase producers (KPC, NDM, VIM, IMP, OXA…). It can even detect weakly expressed carbapenemases like OXA-244and OXA-48. |
|
|
|
|
|
|
|
|
|
|
|
🎯 Highly selective and specific |
|
| The medium inhibits not only beta-lactam susceptible bacteria but also most ESBL and AmpC hyperproducers. |
|
|
|
|
|
|
|
|
|
|
|
🔍 Impressive limit of detection |
| It possesses an impressive limit of detection of 10 CFU/ml. |
|
| | Can be interpreted after 18-24 h of aerobic incubation at 35-37°C. |
|
|
|
|
|
|
|
|
|
|
|
|
DISCOVER MORE ABOUT CHROMagar™ mSuperCARBA™ |
|
|
|  | All you need to know about CHROMagar mSuperCARBA |
| Consult product details, performance, instructions for use, and all related publications. |
|
| |
| |  | Over 80 distributors experts worldwide for you |
|
| The experts CHROMagar would be delighted to speak with you. Find them in your preferred area. |
| |
|
|
|
|
|
|
|
|
|
|
If you have any additional questions regarding our products, distribution, or other inquiries, please do not hesitate to contact us. |
|
|
|
|
|
|
|
|
|
|
|
References
* CRO: Carbapenem-Resistant organism. 1. Carbapenem-resistant Enterobacteriaceae – second update, 26 September 2019, ECDC. 2. CDC, 2019 Antibiotic Resistance Threats Report, Carbapenem-resistant Enterobacteriaceae (CRE) MAR 25/2024. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/cre-508.pdf 3. Daroukh A, Delaunay C, Bigot S, et al. Characteristics and costs of carbapenemase-producing enterobacteria carriers (2012/2013). Med Mal Infect. 2014;44(7):321-326. doi:10. 1016/j.medmal.2014.06.004 4. Otter JA, Burgess P, Davies F, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188-196. doi:10.1016/j.cmi.2016.10.005 5. Garcia-Fernandez et al., 2017. Diagn. Micr. Infect. Dis. |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
